Royalty Pharma (FRA:RPD) Other Operating Expense: €-244 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RPD Royalty Pharma PLC FRA:RPD
72 GF Score
Price €47.87
GF Value €33.11
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Other Operating Expense?

Royalty Pharma FRA:RPD -0.20% 72 Other Operating Expense is €-244 Mil as of Mar. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 72/100 and a GF Value™ of €33.11 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Royalty Pharma's Other Operating Expense for the three months ended in Mar. 2026 was €-174 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-244 Mil.

Royalty Pharma's quarterly Other Operating Expense increased from Sep. 2025 (€11 Mil) to Dec. 2025 (€16 Mil) but then declined from Dec. 2025 (€16 Mil) to Mar. 2026 (€-174 Mil).

Royalty Pharma's annual Other Operating Expense increased from Dec. 2023 (€514 Mil) to Dec. 2024 (€700 Mil) but then declined from Dec. 2024 (€700 Mil) to Dec. 2025 (€-177 Mil).

Royalty Pharma Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Other Operating Expense Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only 421.12 858.96 514.12 699.50 -176.61

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117.60 -96.59 10.99 16.09 -174.03
FRA:RPD
72GF Score
Royalty Pharma PLC FRA:RPD
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-244 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €-244 Mil mean?
Royalty Pharma (FRA:RPD) has a Other Operating Expense of €-244 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Other Operating Expense too high?
Royalty Pharma's current Other Operating Expense is €-244 Mil. Overall, Royalty Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Other Operating Expense compare to ROIV and MRNA?
Royalty Pharma's Other Operating Expense of €-244 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Other Operating Expense is €-244 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €33.11, compared to a current price of €47.87 — trading 44.6% above its estimated fair value. The current Other Operating Expense is €-244 Mil. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Other Operating Expense is €-244 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €47.87 is trading 44.6% above its estimated GF Value™ of €33.11. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Other Operating Expense: €-244 Mil
  • GF Value™: €33.11 vs. price of €47.87 (44.6% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for FRA:RPD

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.87
Price
€33.11
GF Value